REVAMP:Response evaluation in myeloma using 18F-FDG PET/MRI

• Research type

  Research Study

• Full title

  Response evaluation in myeloma patients using integrated 18F-Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI): The REVAMP study

• IRAS ID

  199518

• Contact name

  Vicky Goh

• Contact email

  vicky.goh@kcl.ac.uk

• Sponsor organisation

  King's College London (KCL)

• Duration of Study in the UK

  5 years, 0 months, 1 days

• Research summary

  Myeloma, a form of blood cancer, is a debilitating disease affecting 4,800 patients per year [CRUK 2014]. Patients suffer from bone pain due to destructive bone lesions. Imaging plays an important role via lesion detection, therapy triage and response assessment. Skeletal survey, involving x-rays of the entire skeleton [Dimopoulos, Blood, 2011] has been the 'gold standard' but recent studies have shown it only has a sensitivity of 30% for lesion detection [Regelink et al, 2013].
  Magnetic resonance imaging (MRI) may improve on this (80% versus 30% sensitivity, [Regelink, 2013]). Whole body MRI, where the skeleton can be imaged from skull base to knees, is now possible and recommended in the 2015 International Myeloma Working Group (IMWG) guidelines for baseline staging in myeloma [Dimopoulos, 2015].
  For treatment response assessment a study has suggested that FDG PET/CT may better than MRI alone for assessment of response/non-response [Spinnato, 2012]].
  Position Emission Tomography/MR (PET/MRI) is a new scanner that combines MRI and PET imaging. PET may highlight myeloma as areas of increased glucose metabolism, whilst the MR component provides an anatomic map. We hypothesize that PET/MRI will improve staging and treatment response assessment. We wish to evaluate newly diagnosed myeloma patients planned for bone marrow transplantation, and compare this to PET/CT. We will develop software to quantify tumour volume pre and post-induction chemotherapy and to assess changes in tumour function/composition e.g. metabolism, cellularity and fat content, as we hypothesize that these may change with treatment.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  16/SC/0428

• Date of REC Opinion

  14 Oct 2016

• REC opinion

  Further Information Favourable Opinion